REVIEW ARTICLE

A Comprehensive Review on Synergistic Polyherbal Strategies for Parkinson's Disease: Advances in Formulation, Standardization, and Artificial Intelligence-integrated Phytopharmaceutical Development

Habeeba Sulthana[1], Saravanan Ravindiran[2], S. Anbuselvi[3], Shaik Harun Rasheed[4]

[1]Department of Pharmacology, Bharath Institute of Higher Education and Research BIHER, Chennai, Tamil Nadu, India, [2]Department of Pharmaceutics, Bharath Institute of Higher Education and Research BIHER, Chennai, Tamil Nadu, India, [3]Department of IBT, Bharath Institute of Higher Education and Research BIHER, Chennai, Tamil Nadu, India, [4]Department of Pharmaceutics, School of Pharmacy, Guru Nanak Institutions of Technical Campus (Autonomus), Ibrahimpatnam, Telangana, India

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative condition characterized by dopaminergic neuronal loss, α-synuclein aggregation, mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation. Despite significant advances in symptomatic management, including levodopa-based pharmacotherapy and device-assisted interventions, no currently approved treatment effectively halts or reverses disease progression. The multifactorial nature of PD underscores the need for multi-target therapeutic strategies capable of modulating interconnected pathogenic pathways. Medicinal plants and polyherbal formulations offer a promising complementary approach due to their diverse phytochemical profiles and pleiotropic biological activities. Botanicals such as *Mucuna pruriens*, *Withania somnifera*, *Curcuma longa*, *Ginkgo biloba*, and *Bacopa monnieri* demonstrate antioxidant, anti-inflammatory, mitochondrial-stabilizing, and neuroprotective properties relevant to PD pathology. However, challenges related to phytochemical variability, bioavailability limitations, lack of standardization, and insufficient clinical validation hinder translational advancement. This review critically examines the formulation strategies, standardization requirements, preclinical and clinical evaluation models, and regulatory considerations necessary for developing synergistic anti-Parkinsonian herbal therapies. Furthermore, the role of artificial intelligence (AI) in accelerating phytopharmaceutical discovery is highlighted, including network pharmacology modeling, phytochemical-target prediction, synergy optimization, quality control analytics, and precision phytotherapy. The integration of computational intelligence with evidence-based herbal medicine represents a transformative paradigm for developing standardized, safe, and mechanistically validated polyherbal formulations for PD management.

Key words: Artificial intelligence, Parkinson's disease, phytopharmaceutical standardization, polyherbal formulations, synergistic therapy

INTRODUCTION

Rationale for exploring plant-based synergistic therapies in Parkinson's disease (PD)

PD is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta and the pathological aggregation

Address for correspondence:
Habeeba Sulthana, Department of Pharmacology, Bharath Institute of Higher Education and Research BIHER, Chennai - 600 073, Tamil Nadu, India.
E-mail: habeebapharma@gmail.com

Received: 17-05-2026
Revised: 21-06-2026
Accepted: 28-06-2026

of α-synuclein into Lewy bodies.[1] The resulting dopamine depletion in the striatum produces classical motor symptoms such as bradykinesia, resting tremor, rigidity, and postural instability, along with a spectrum of non-motor manifestations including cognitive decline, sleep disturbances, mood disorders, and autonomic dysfunction.[2] Importantly, PD is not a single-pathway disease; it involves oxidative stress, mitochondrial dysfunction, neuroinflammation, impaired proteostasis, excitotoxicity, and genetic susceptibilities acting in concert.[3]

Current pharmacological strategies largely rely on dopamine replacement or modulation. While levodopa and related dopaminergic agents provide substantial symptomatic relief, they do not halt neurodegeneration and frequently lead to long-term complications such as motor fluctuations and dyskinesia.[4] Moreover, many non-motor symptoms remain inadequately controlled. This therapeutic gap underscores the urgent need for multi-target disease-modifying strategies rather than single-mechanism symptomatic approaches.

Medicinal plants and phytoconstituents present a compelling alternative because they inherently contain multiple bioactive compounds capable of acting on diverse molecular targets simultaneously.[5] Phytochemicals such as alkaloids, flavonoids, terpenoids, polyphenols, and with anolides exhibit antioxidant, anti-inflammatory, anti-apoptotic, mitochondrial stabilizing, and neuroprotective properties.[6] Unlike synthetic mono-target drugs, plant-based therapies may offer synergistic interactions where combined phytochemicals produce enhanced therapeutic efficacy compared to isolated constituents. Such synergy may be particularly advantageous in PD, where pathological cascades are interconnected and multifactorial.[7]

Furthermore, traditional medicine systems have long employed polyherbal formulations for neurological disorders, suggesting empirical evidence of combinatorial therapeutic strategies. The concept of synergistic phytotherapy aligns well with systems biology, where modulation of multiple nodes within a pathological network may yield superior disease control compared to targeting a single enzyme or receptor.[8] Therefore, exploring plant-based synergistic interventions represents a rational and biologically coherent direction for anti-Parkinsonian drug development.

Need for standardization and scientific validation of herbal interventions

Despite the therapeutic promise of medicinal plants, the transition from traditional usage to scientifically validated phytopharmaceuticals presents significant challenges. Herbal preparations often suffer from variability in phytochemical composition due to differences in geographical origin, cultivation practices, harvesting time, post-harvest processing, and extraction methods. Such variability can result in inconsistent therapeutic outcomes and safety profiles.[9]

Standardization is therefore essential to ensure reproducibility, efficacy, and safety. This involves identification of marker compounds, quantitative phytochemical profiling, chromatographic fingerprinting, and validation of extraction procedures.[10] Advanced analytical tools such as high-performance liquid chromatography (HPLC), liquid chromatography-tandem mass spectrometry (LC-MS/MS), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance (NMR) spectroscopy play critical roles in characterizing active constituents and establishing batch-to-batch consistency.[11] Without such measures, it becomes difficult to correlate pharmacological effects with specific phytochemical signatures.

In addition, rigorous preclinical and clinical evaluation is indispensable. *In vitro* neuronal models, toxin-induced animal models of Parkinsonism, behavioral assays, biomarker analysis, and controlled human trials are necessary to substantiate neuroprotective claims.[12] Toxicological assessment, herb-drug interaction studies, and pharmacokinetic profiling are equally important, especially when herbal formulations are co-administered with conventional dopaminergic medications.[13]

Another critical aspect is the extraction methodology. Conventional extraction techniques may degrade thermolabile compounds or fail to efficiently isolate bioactive fractions, thereby reducing potency. Inadequate standardization of extraction parameters such as solvent selection, temperature, time, and particle size can compromise therapeutic consistency. Hence, optimized extraction strategies and validated formulation approaches are essential to convert promising botanicals into reliable anti-Parkinsonian products.[14]

Role of artificial intelligence (AI) in modern Phytopharmaceutical research

The complexity of both PD pathophysiology and phytochemical composition necessitates integrative and data-driven approaches. AI has emerged as a transformative tool capable of bridging traditional herbal knowledge with modern pharmacological science.[15]

AI-based network pharmacology enables mapping of phytochemical-target-pathway interactions, allowing researchers to identify multi-target mechanisms underlying synergistic effects. Machine learning algorithms can analyze large-scale omics datasets to uncover correlations between plant metabolites and disease-associated molecular networks.[16] Such approaches facilitate rational selection of medicinal plants based on predicted modulation of PD-relevant pathways such as mitochondrial dysfunction, oxidative stress signaling, and neuroinflammatory cascades.

In formulation science, AI can optimize extraction conditions, predict solubility and permeability of phytoconstituents, and

model stability profiles.[17] Spectral data from chromatographic and mass spectrometric analyses can be processed using pattern recognition and deep learning (DL) techniques to ensure rapid and precise quality control. Predictive toxicology models further assist in identifying potential safety concerns and herb-drug interactions before clinical deployment.[18]

Moreover, AI can integrate clinical, pharmacological, and ethnobotanical databases to identify novel synergistic plant combinations. By employing graph neural networks (GNNs) and multi-omics integration frameworks, it becomes possible to design precision phytotherapy strategies tailored to specific molecular subtypes of PD.[19] This convergence of computational intelligence with phytomedicine opens new avenues for developing scientifically robust, standardized, and synergistic anti-Parkinsonian herbal formulations.

PD: CLINICAL AND BIOLOGICAL OVERVIEW

Epidemiology and global disease burden

The burden of PD extends beyond motor disability, encompassing cognitive decline, psychiatric manifestations, sleep disturbances, and autonomic dysfunction, all of which substantially impair quality of life.[20]

The socioeconomic impact is profound, including long-term healthcare expenditure, caregiver burden, loss of productivity, and institutional care requirements. In low- and middle-income countries, limited access to specialist care and advanced therapies further exacerbates disability-adjusted life years.[21] With aging populations expanding globally, projections suggest that PD prevalence will continue to increase substantially over the coming decades, reinforcing the urgency for disease-modifying interventions rather than purely symptomatic therapies.[22]

Pathophysiology of PD

The neuropathological hallmark of PD is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine deficiency and impaired basal ganglia circuitry.[23] However, contemporary understanding recognizes PD as a multi-system disorder involving widespread neuronal networks and complex molecular cascades [Figure 1].

Dopaminergic neurodegeneration

Loss of nigrostriatal dopaminergic neurons disrupts the balance between the direct and indirect pathways of the basal ganglia, resulting in motor impairment. Dopamine depletion reduces activation of D1 receptor-mediated excitatory pathways while enhancing inhibitory output through D2 receptor dysregulation.[24]

α-Synuclein aggregation and Lewy bodies

Misfolding and aggregation of α-synuclein into intracellular Lewy bodies represent a central pathological feature. Abnormal protein aggregation disrupts synaptic vesicle trafficking, mitochondrial function, and proteasomal degradation pathways. The prion-like propagation hypothesis suggests that misfolded α-synuclein may spread trans-synaptically, contributing to disease progression across interconnected brain regions. This progressive spread aligns with Braak staging, where pathology ascends from the brainstem to cortical areas.[25]

Oxidative stress and mitochondrial dysfunction

Oxidative stress plays a critical role in dopaminergic neuron vulnerability. Dopamine metabolism itself generates reactive oxygen species (ROS), and impaired mitochondrial complex I activity further amplifies oxidative damage.

Neuroinflammation and microglial activation

Chronic activation of microglia contributes to sustained neuroinflammatory responses within the substantia nigra. Elevated levels of proinflammatory cytokines, nitric oxide, and reactive oxygen intermediates exacerbate neuronal injury. Neuroinflammation is increasingly recognized not merely as a secondary phenomenon but as a contributing driver of neurodegeneration, creating a vicious cycle of inflammatory signaling and neuronal loss.

Genetic and environmental risk factors

Although most PD cases are sporadic, several genetic mutationsincluding those in SNCA, LRRK2, PARK2 (parkin), PINK1, and GBA, have clarified disease mechanisms. These genes are largely associated with mitochondrial maintenance, protein degradation, and lysosomal function. Environmental exposures such as pesticides, heavy metals, and rural toxins may further interact with genetic susceptibilities to initiate pathogenic cascades.[26]

Clinical manifestations

Motor symptoms

The classical motor triad consists of resting tremor, bradykinesia, and muscular rigidity, often accompanied by postural instability in later stages. Bradykinesia is essential for clinical diagnosis and reflects impaired voluntary movement initiation. Tremor typically presents asymmetrically and may diminish with purposeful activity. As the disease progresses, gait disturbances and freezing episodes become prominent.[27]

Non-motor symptoms

Non-motor symptoms frequently precede motor manifestations and include anosmia, constipation, REM sleep behavior disorder, depression, anxiety, cognitive impairment, and autonomic dysfunction. These features significantly reduce



Figure 1: Pathophysiology of Parkinson's disease

quality of life and may be less responsive to dopaminergic therapy, highlighting the multi-system nature of PD.[28]

Disease progression and staging

Disease progression varies considerably among individuals. Clinical staging systems, such as the Hoehn and Yahr scale, categorize severity based on motor involvement and functional impairment. As pathology extends to cortical and limbic regions, cognitive decline and neuropsychiatric complications may develop. The heterogeneity of progression underscores the need for personalized and multi-target therapeutic strategies.[29]

CURRENT THERAPEUTIC STRATEGIES AND THEIR LIMITATIONS

Pharmacological management

The cornerstone of therapy for PD remains pharmacological dopamine replacement. Levodopa (L-DOPA), typically administered with peripheral decarboxylase inhibitors such as carbidopa or benserazide, is the most effective agent for alleviating motor symptoms. Once transported across the blood-brain barrier (BBB), levodopa is converted to dopamine, temporarily restoring striatal neurotransmission and improving bradykinesia and rigidity.[30]

Despite their effectiveness, these agents are fundamentally symptomatic and do not halt the progressive loss of dopaminergic neurons. Long-term levodopa therapy is associated with motor fluctuations ("on-off" phenomena) and levodopa-induced dyskinesias. Dopamine agonists may cause impulse control disorders, hallucinations, and orthostatic hypotension, particularly in elderly patients.[31] Furthermore, many non-motor symptoms, including cognitive impairment, autonomic dysfunction, and mood disturbances, remain insufficiently addressed by dopaminergic therapies.

Surgical and device-based interventions

For patients with advanced disease and refractory motor complications, surgical interventions such as deep-brain stimulation (DBS) offer substantial benefit. DBS targets structures such as the subthalamic nucleus or globus pallidus interna, modulating abnormal basal ganglia circuitry through high-frequency electrical stimulation.[32]

Long-term complications and therapeutic gaps

The progressive nature of PD ensures that even initially effective therapies lose optimal efficacy over time. Motor complications typically emerge after prolonged levodopa exposure, reflecting pulsatile dopamine stimulation and maladaptive synaptic plasticity. Dyskinesias and unpredictable motor fluctuations significantly impair quality of life and complicate treatment regimens.[33]

Another limitation is the economic and healthcare burden associated with long-term pharmacotherapy and advanced device-based treatments. In many regions, consistent access to medication and specialized care is limited. In addition, polypharmacy increases the risk of adverse drug reactions and drug-drug interactions, particularly in elderly populations with comorbidities.[34]

These therapeutic gaps underscore the need for alternative or adjunct strategies capable of addressing multiple pathological

mechanisms simultaneously. Approaches that combine antioxidant, anti-inflammatory, mitochondrial stabilizing, and neuroprotective actions may offer broader disease coverage than dopamine-centric therapies alone.

RATIONALE FOR HERBAL AND POLYHERBAL APPROACHES IN PD

Multi-target mechanistic advantage of phytoconstituents

The multifactorial pathogenesis of PD necessitates therapeutic strategies capable of modulating multiple molecular pathways simultaneously.[1] Unlike conventional mono-target pharmacological agents, medicinal plants contain complex mixtures of bioactive phytoconstituents, including alkaloids, flavonoids, polyphenols, terpenoids, saponins, and glycosidesthat collectively exert pleiotropic biological effects.[35]

Many plant-derived compounds demonstrate antioxidant properties by scavenging ROS, enhancing endogenous antioxidant enzymes such as superoxide dismutase and catalase, and inhibiting lipid peroxidation.[36] Others exhibit anti-inflammatory actions through suppression of proinflammatory cytokines (e.g., tumor necrosis factor-alpha, interleukin-1β) and modulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways. Certain phytochemicals influence mitochondrial stability, regulate apoptotic cascades (Bax/Bcl-2 balance), and enhance neurotrophic factor expression.[37]

Neuroprotective, antioxidant, and anti-inflammatory potential

Several medicinal plants traditionally used in neurological disorders exhibit mechanistic relevance to PD. For example, *Mucuna pruriens* provides a natural source of L-DOPA, directly addressing dopamine deficiency. *Withania somnifera* contains with anolides that demonstrate neuroprotective and anti-inflammatory activity in experimental models. *Curcuma longa* (curcumin) modulates oxidative stress and inflammatory signaling, while *Ginkgo biloba* exhibits antioxidant and neurovascular protective effects.[38]

Beyond symptomatic dopamine restoration, these botanicals may influence mitochondrial bioenergetics, reduce α-synuclein aggregation, and enhance neuronal resilience. Importantly, the combined presence of multiple bioactive compounds within a single extract may yield additive or synergistic neuroprotective effects.[39]

Synergy may occur through pharmacodynamic interactions (multiple compounds acting on complementary pathways) or pharmacokinetic interactions (one constituent enhancing absorption or stability of another). This holistic interaction aligns with network pharmacology principles, wherein disease networks are modulated at multiple nodes rather than a single receptor target.[40]

Concept of synergistic phytotherapy

Synergistic phytotherapy refers to the strategic combination of two or more medicinal plants to achieve enhanced therapeutic outcomes beyond the sum of their individual effects. In the context of PD, a rational polyherbal formulation might combine:

- A dopaminergic support component (e.g., natural L-DOPA source)
- An antioxidant-rich extract to mitigate ROS-mediated damage
- An anti-inflammatory agent targeting microglial activation
- A mitochondrial stabilizer to enhance neuronal survival.[41]

However, synergistic formulations must be scientifically validated. Without controlled experimentation, the assumption of synergy remains speculative. Quantitative synergy assessment modelssuch as isobolographic analysis and combination index methodsshould be employed in preclinical studies to substantiate combinatorial benefits.

Traditional medicine systems and ethnopharmacological evidence

Traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, and Unani medicine have long utilized plant-based preparations for neurological disorders characterized by tremors and motor dysfunction. In Ayurveda, conditions resembling Parkinsonism (e.g., "Kampavata") are treated with herbal combinations aimed at restoring systemic balance.[42]

Ethnopharmacological knowledge provides valuable leads for modern drug discovery. However, empirical use alone is insufficient for regulatory approval or clinical adoption. Bridging traditional knowledge with modern pharmacology requires rigorous phytochemical characterization, mechanistic validation, dose optimization, and controlled clinical evaluation.[43]

SELECTED MEDICINAL PLANTS WITH ANTI-PARKINSONIAN POTENTIAL

M. pruriens

M. pruriens (velvet bean) is one of the most extensively studied medicinal plants in relation to Parkinsonian disorders. The seeds contain significant concentrations of natural

L-DOPA, the metabolic precursor of dopamine and the gold-standard pharmacotherapy for PD. In addition to L-DOPA, the plant contains alkaloids, flavonoids, tannins, and antioxidant compounds that may contribute to neuroprotective effects beyond dopamine replacement [Figure 2].

Preclinical studies demonstrate that *M. pruriens* extracts reduce oxidative stress markers, improve mitochondrial enzyme activity, and attenuate dopaminergic neuronal loss in toxin-induced animal models. Some clinical investigations suggest faster onset of action and prolonged "on" time compared to synthetic levodopa formulations; however, variability in L-DOPA concentration across preparations presents a significant challenge. Unstandardized products may result in unpredictable dosing and risk of dyskinesia or interaction with prescribed dopaminergic medications. Therefore, rigorous phytochemical standardization and controlled clinical trials are essential before widespread therapeutic adoption.[44]

W. somnifera

W. somnifera, commonly known as ashwagandha, is a well-recognized adaptogenic herb in Ayurvedic medicine. Its major bioactive constituents, withanolides, exhibit antioxidant, anti-inflammatory, anti-apoptotic, and neurotrophic properties. Experimental models suggest that ashwagandha may reduce α-synuclein aggregation, enhance mitochondrial function, and modulate neuroinflammatory pathways.[45]

Unlike *M. pruriens*, ashwagandha does not directly supply dopamine precursors but instead targets upstream pathogenic mechanisms. It may therefore serve as a neuroprotective adjunct in polyherbal formulations. Preclinical evidence supports its ability to improve motor performance and reduce oxidative biomarkers in Parkinsonian models.[46] However, robust clinical trials specifically in PD populations remain limited, necessitating further translational research.

C. longa

C. longa (turmeric) contains curcuminoids, particularly curcumin, known for potent antioxidant and anti-inflammatory activity. Curcumin modulates NF-κB signaling, inhibits microglial activation, and reduces lipid peroxidation. In addition, it has been shown to interfere with α-synuclein aggregation and amyloid fibril formation in experimental systems.

A significant limitation of curcumin is poor bioavailability due to low aqueous solubility and rapid metabolism. Advanced formulation strategies such as nanoparticles, liposomes, and phytosomes have been explored to enhance systemic exposure. Its multi-target action makes it a promising component in synergistic anti-Parkinsonian formulations.[47]

G. biloba

Extracts of *G. biloba* leaves are rich in flavonoids and terpenoids, particularly ginkgolides and bilobalide. These constituents possess antioxidant, anti-inflammatory, and neurovascular protective properties. Experimental evidence indicates that Ginkgo extract may attenuate dopaminergic neuron loss and improve behavioral outcomes in toxin-induced Parkinsonian models.[48]

Bacopa monnieri

B. monnieri contains bacosides that exhibit antioxidant and neuroprotective properties. While traditionally used for cognitive enhancement, its relevance in PD lies in mitigating oxidative stress and supporting neuronal plasticity. It may be particularly beneficial in addressing non-motor cognitive symptoms associated with disease progression.[49]



Figure 2: Medicinal plants with anti-Parkinsonian potential

Comparative mechanistic mapping of selected plants

Collectively, these medicinal plants target complementary aspects of Parkinsonian pathology. *M. pruriens* primarily addresses dopaminergic deficiency; *W. somnifera* and *C. longa* modulate oxidative stress and inflammation; *G. biloba* supports neurovascular integrity; and *B. monnieri* contributes neurocognitive support.

From a systems pharmacology perspective, a rational polyherbal formulation incorporating these plants could theoretically modulate dopamine synthesis, mitochondrial stability, inflammatory cascades, and oxidative stress simultaneously. However, such combinations must be optimized to avoid pharmacokinetic interference, toxicity, or herb-drug interactions. Quantitative synergy testing and AI-assisted network analysis could guide rational dose selection and mechanistic validation.[50]

MARKETED PLANT-BASED PRODUCTS FOR PD

In addition to investigational use in traditional systems, plant-based supplements aimed at supporting neurological function and Parkinson's symptoms are increasingly available in the nutraceutical market. Many of these products focus on botanicals such as *M. pruriens* (a natural source of L-DOPA), *W. somnifera* (adaptogen), and other herbal combinations reputed to support dopaminergic balance, antioxidant capacity, or overall neurological health. *M. pruriens* seeds have traditionally been used in Ayurvedic regimens for Parkinson-like disorders due to their levodopa content, but the actual L-DOPA levels in commercial products may vary widely and are often unregulated in many supplement markets.

Plant-based supplements commonly available

M. pruriens capsules triple strength 1500 mg per serving

High-strength *M. pruriens* extract often marketed for dopamine support and neurological wellness. Products of this type are chosen for their concentrated botanical L-DOPA content, although standardized levodopa percentages are not always disclosed on labels.[51]

Saptamveda Natural Kaunch Beej Extract 500 mg

Capsule supplement featuring kaunch beej (*M. pruriens*) extract; dietary support for mood and general well-being rather than clinically established Parkinson's therapy.

Swanson full spectrum M. pruriens

A popular full-spectrum *Mucuna* extract capsule widely used as an herbal mood and neurological support supplement.

Inlife Shilajit + Ashwagandha + Safed Musli + Mucuna Prurita capsules

A multi-herb Ayurvedic blend combining adaptogens and *Mucuna* components, typically marketed for energy and nervous system support.

Pelvox: St John's Wort, Ashwagandha, MucunaPruriens

Another blended botanical supplement combining herbs reputed to support mood, stress resilience, and neurological balance.

Healthy hey nutrition Kapikachhu M. pruriens extract

Standard herbal extract of *M. pruriens* marketed primarily as a dopamine precursor supplement.

VPGRASSY Kaunch Beej Paak

Traditional *M. pruriens* paak (preparation) typically promoted for energy and rejuvenation; it may be consumed as part of broader herbal regimens.

Himalaya Organic Ashwagandha

A standardized *W. somnifera* extract known for adaptogenic activity, stress support, and generalized nervous system benefits; often used alongside other herbals, though not specifically labeled for Parkinson's.[52]

QUALITY VARIABILITY, LABELING, AND REGULATORY CHALLENGES

Despite the growing availability of these products, a key concern for Parkinson's research and clinical use is variability in active phytochemical content and labeling accuracy. Independent analyses of commercial *M. pruriens* supplements have shown wide variability in levodopa content among products, meaning that actual therapeutic doses may differ significantly from label claims.[53] Without standardized markers and rigorous quality control, consumer use may result in unpredictable dosing and efficacy.

Formulation strategies for herbal anti-Parkinsonian products

The successful translation of medicinal plants into effective anti-Parkinsonian therapies depends not only on pharmacological potential but also on rational formulation design. Many phytoconstituents exhibit poor aqueous solubility, limited permeability across the BBB, rapid metabolism, and low systemic bioavailability.[54] Therefore, advanced formulation strategies are essential to enhance therapeutic efficacy, ensure dose consistency, and optimize central nervous system (CNS) delivery.

Challenges in herbal drug delivery

Phytochemicals such as curcumin, with anolides, flavonoids, and various alkaloids often suffer from low oral bioavailability due to poor solubility, intestinal degradation, and first-pass metabolism. In addition, achieving sufficient brain concentrations is a major challenge because the BBB restricts the entry of many polar or high-molecular-weight compounds.[55]

For botanical extracts containing multiple constituents, additional complexity arises from chemical instability, interaction between components, and variability in pharmacokinetics. In polyherbal formulations, synergistic combinations must be optimized to avoid antagonistic absorption effects or altered metabolic profiles.[43]

Another critical issue is dose standardization. When using plant materials such as *M. pruriens*, variability in natural L-DOPA content necessitates precise quantitative analysis and controlled formulation to prevent subtherapeutic dosing or adverse dopaminergic effects [Figure 3].

Bioavailability enhancement approaches

To overcome pharmacokinetic limitations, several advanced delivery systems have been explored for herbal neurotherapeutics. The enhanced delivery systems are presented in Figure 4.

Nanoparticles

Polymeric or lipid-based nanoparticles improve solubility, protect phytoconstituents from degradation, and enhance BBB penetration. Controlled release properties allow sustained drug levels, reducing dosing frequency.

Liposomes

Phospholipid vesicles encapsulate hydrophilic and lipophilic compounds, enhancing stability and facilitating targeted CNS delivery.

Phytosomes

Complexes formed between phospholipids and phytochemicals improve membrane permeability and systemic absorption, particularly for polyphenolic compounds.

Nanoemulsions

These colloidal systems enhance the dissolution of poorly soluble phytochemicals and improve gastrointestinal absorption.

Solid dispersions

Amorphous dispersions increase dissolution rate and bioavailability of hydrophobic plant constituents.

These technologies are particularly relevant for compounds such as curcumin and withanolides, which exhibit strong neuroprotective potential but limited oral bioavailability in conventional forms.[56]

Polyherbal formulation design for synergistic activity

Designing a synergistic anti-Parkinsonian polyherbal formulation requires strategic selection of components targeting complementary pathological pathways. A rational design framework may include:

- A dopaminergic precursor source (e.g., standardized *M. pruriens* extract)
- An antioxidant/anti-inflammatory agent (e.g., curcumin-rich extract)
- A mitochondrial stabilizer and adaptogen (e.g., *W. somnifera*)
- A neurovascular support component (e.g., *G. biloba*).

Optimization involves determining appropriate ratios to maximize pharmacodynamic synergy while minimizing toxicity or herb-drug interactions. Quantitative combination studies using isobolographic analysis or combination index models are recommended to validate synergistic effects



Figure 3: Challenges in herbal drug delivery



Figure 4: Advanced drug delivery systems for Phytoconstituents

in vitro and *in vivo*. In addition, excipient compatibility, stability under various environmental conditions, and shelf-life studies are essential for ensuring product integrity over time.[57]

Stability, compatibility, and shelf-life considerations

Herbal extracts are chemically complex and may contain thermolabile or photosensitive constituents. Factors such as moisture, pH, temperature, and light exposure can degrade active compounds, leading to reduced potency.[58]

STANDARDIZATION AND QUALITY CONTROL OF HERBAL FORMULATIONS

The therapeutic credibility of herbal anti-Parkinsonian formulations depends fundamentally on rigorous standardization and quality control. Unlike synthetic single-molecule drugs, botanical preparations are complex mixtures of multiple phytoconstituents whose concentrations may vary due to geographical origin, cultivation practices, harvesting season, drying methods, and extraction procedures. Without robust analytical validation, variability can compromise reproducibility, safety, and clinical reliability. Therefore, systematic standardization strategies are indispensable in the development of phytopharmaceutical interventions targeting PD.[59]

Phytochemical profiling and marker compound selection

Standardization begins with the identification and quantification of bioactive marker compounds. For example, L-DOPA serves as a primary marker in *M. pruriens* formulations, while with anolides are commonly used as markers in *W. somnifera* extracts. Curcuminoids represent marker constituents for *C. longa*, and flavonol glycosides (e.g., quercetin derivatives) are often quantified in *G. biloba* extracts.

Marker selection should be guided by pharmacological relevance, stability, detectability, and correlation with biological activity. In polyherbal formulations, multiple markers may be required to represent each botanical component adequately. Quantitative standardization ensures batch-to-batch consistency and supports dose reproducibility in clinical evaluation.

Chromatographic and spectroscopic techniques

Modern analytical technologies provide the backbone for phytochemical characterization. HPLC is widely employed for quantitative estimation of marker compounds. LC-MS/MS enables sensitive detection and structural confirmation of phytoconstituents, even in complex matrices. GC-MS is particularly useful for volatile components, while NMR spectroscopy facilitates structural elucidation and purity assessment. Chromatographic fingerprinting is especially valuable for polyherbal formulations, as it provides a comprehensive chemical profile rather than focusing solely on isolated markers. Pattern recognition and chemometric analysis can further enhance discrimination between authentic and adulterated samples.[60]

Parameters such as solvent selection, extraction time, temperature, and pH must be optimized and documented. Standard operating procedures (SOPs) should govern each stage of manufacturing to minimize variability. In polyherbal combinations, compatibility testing between extracts must be conducted to detect potential chemical degradation or precipitation.[61]

Toxicological and safety evaluation

Although medicinal plants are often perceived as inherently safe, phytoconstituents may exert dose-dependent toxicity or interact with conventional medications. For example, botanical sources containing L-DOPA may interact with prescribed dopaminergic therapies, altering pharmacokinetic profiles and increasing dyskinesia risk.[62]

Regulatory frameworks and compliance

Regulatory classification of herbal products varies globally. Some jurisdictions categorize them as dietary supplements, while others regulate them as traditional or phytopharmaceutical drugs. For clinical development and broader therapeutic acceptance, compliance with pharmacopeial standards and regulatory guidelines is essential.[63]

Dossier preparation should include detailed documentation of raw material sourcing, phytochemical analysis, stability studies, toxicological data, and clinical evidence. International harmonization efforts emphasize the importance of quality, safety, and efficacy documentation before market authorization.

Integration of AI in quality control

AI can significantly enhance quality assurance in phytopharmaceutical development. Machine learning algorithms applied to chromatographic and spectral datasets can detect subtle deviations in chemical fingerprints, enabling rapid authentication and adulteration detection. AI-based predictive models can optimize extraction conditions and forecast stability trends based on historical data.[64]

PRECLINICAL AND CLINICAL EVALUATION MODELS

The transition of herbal anti-Parkinsonian formulations from conceptual design to therapeutic application requires rigorous experimental validation across multiple biological systems. Given the multifactorial pathology of PD, evaluation strategies must assess dopaminergic integrity, oxidative stress modulation, neuroinflammation, mitochondrial function, and behavioral outcomes. A translational framework integrating *in vitro* assays, animal models, biomarker analysis, and controlled clinical trials is essential to substantiate efficacy and safety.

In vitro models of neurodegeneration

In vitro systems provide an initial platform to evaluate neuroprotective potential and mechanistic pathways. Human neuroblastoma SH-SY5Y cells and dopaminergic neuronal cultures are commonly employed to simulate Parkinsonian neurotoxicity. Neurodegeneration may be induced using toxins such as 6-hydroxydopamine, rotenone, or MPP+, which mimic mitochondrial impairment and oxidative stress.

Herbal extracts and isolated phytoconstituents can be assessed for:

- Reduction of ROS
- Preservation of mitochondrial membrane potential
- Inhibition of apoptosis (Bax/Bcl-2 modulation)
- Suppression of pro-inflammatory cytokine expression
- Inhibition of α-synuclein aggregation.

Quantitative assays such as MTT viability testing, flow cytometry, Western blotting, ELISA, and immunofluorescence imaging are commonly utilized. For polyherbal formulations, combination index models can help determine synergistic neuroprotective effects at the cellular level.[65]

Animal models of PD

Animal models are critical for evaluating behavioral and neurochemical outcomes. Toxin-induced models remain widely used due to their reproducibility:

Behavioral assessments include rotarod performance, open field tests, gait analysis, and grip strength measurement. Biochemical analysis of striatal dopamine levels, tyrosine hydroxylase immunostaining, oxidative stress markers, and inflammatory cytokines provides mechanistic validation.[66]

Integration of AI in preclinical and clinical evaluation

AI can strengthen evaluation pipelines by analyzing high-dimensional datasets generated from behavioral assays, imaging, metabolomics, and transcriptomics. Machine learning models can identify predictive biomarkers of response, stratify patient subgroups, and optimize dosing strategies.[67]

AI IN HERBAL ANTI-PARKINSONIAN DRUG DISCOVERY

The complexity of both PD pathophysiology and multi-component herbal formulations necessitates computational strategies capable of integrating high-dimensional biological data. AI, encompassing machine language, DL, network pharmacology, and systems biology modeling, provides a transformative framework for accelerating phytopharmaceutical discovery. Unlike conventional reductionist drug development, AI enables simultaneous analysis of multi-target interactions, phytochemical diversity, and disease-network modulation, aligning well with the principles of synergistic herbal therapeutics [Figure 5].

AI-driven network pharmacology for multi-target prediction

Network pharmacology models treat diseases as interconnected molecular networks rather than single-gene defects. In PD, pathological nodes include mitochondrial dysfunction, α-synuclein aggregation, oxidative stress



Figure 5: Artificial intelligence in herbal anti-Parkinsonian drug discovery

signaling, neuroinflammatory pathways, and apoptotic cascades. AI-based algorithms can map phytochemicals from medicinal plants to predicted protein targets using molecular docking, GNNs, and protein-ligand interaction databases.[68]

By constructing herb-compound-target-pathway networks, researchers can identify overlapping or complementary mechanisms among botanical constituents. For example, one phytochemical may modulate NF-κB signaling while another stabilizes mitochondrial complex I, together exerting synergistic neuroprotective effects. Network topology analysis (degree centrality, betweenness, clustering coefficients) helps prioritize key molecular hubs for experimental validation.

Machine learning for herb-disease correlation analysis

Machine learning models trained on biomedical literature, omics datasets, and clinical databases can detect non-obvious correlations between plant metabolites and PD-associated molecular signatures. Techniques such as random forest classification, support vector machines, and deep neural networks can integrate transcriptomic, proteomic, and metabolomic datasets to predict therapeutic relevance.[69]

For example, gene expression profiles from PD patient samples can be compared with phytochemical-induced gene modulation signatures to identify potential reversal patterns. Such computational repurposing strategies enable rapid prioritization of candidate botanicals before extensive laboratory screening.

Natural language processing (NLP) models further assist in mining ethnopharmacological texts, clinical reports, and pharmacovigilance data to extract evidence linking specific herbs to neurological outcomes.[70]

AI in phytochemical target interaction prediction

AI-enhanced molecular docking and quantitative structure-activity relationship models improve prediction accuracy of phytochemical-protein interactions. DL architectures can analyze three-dimensional structural data to estimate binding affinity, stability, and potential off-target interactions.

In multi-component herbal extracts, AI can rank phytoconstituents based on predicted contribution to dopaminergic modulation, antioxidant activity, or anti-inflammatory potential. Such prioritization streamlines experimental validation and reduces unnecessary screening costs.[71]

AI for formulation optimization

Formulation design of herbal products involves complex parameter spaces, including solvent systems, extraction conditions, excipient compatibility, and delivery system selection. AI-based optimization algorithms, such as Bayesian optimization and genetic algorithms, can efficiently explore formulation variables to maximize solubility, stability, and bioavailability.[72]

Predictive modeling can estimate BBB permeability, dissolution kinetics, and degradation pathways. Machine learning models trained on historical formulation datasets can forecast shelf-life stability and guide selection of encapsulation strategies (e.g., nanoparticles, liposomes, phytosomes).

AI in quality control and spectral analysis

Chromatographic and spectroscopic datasets generated during herbal standardization contain high-dimensional information. AI-driven chemometric analysis can identify subtle deviations in fingerprint patterns, detect adulteration, and ensure batch-to-batch consistency.

Pattern recognition algorithms applied to HPLC or LC-MS data enable automated quality verification. DL-based spectral interpretation can rapidly classify authentic versus substandard products, enhancing regulatory compliance and manufacturing efficiency.[61]

Predictive toxicology and herb-drug interaction modeling

Safety assessment is particularly critical when herbal formulations are co-administered with dopaminergic therapies. AI-based predictive toxicology models can analyze structural alerts and pharmacokinetic features to estimate hepatotoxicity, cardiotoxicity, or neurotoxicity risks.

In silico simulation platforms can model potential herb-drug interactions by predicting cytochrome P450 enzyme modulation, transporter interactions, or competitive metabolic pathways. Early identification of interaction risks enhances clinical safety and regulatory confidence.[73]

Integration of multi-omics data for precision phytotherapy

The future of anti-Parkinsonian herbal therapy lies in precision medicine. AI can integrate genomics, transcriptomics, metabolomics, and clinical phenotyping to stratify patients into molecular subtypes. Such stratification enables targeted phytotherapeutic strategies tailored to dominant pathogenic mechanisms, whether mitochondrial dysfunction, inflammatory dominance, or proteostatic impairment.[74]

Graph-based integrative frameworks allow simultaneous analysis of patient-specific molecular signatures and phytochemical action profiles. This approach supports the concept of personalized polyherbal combinations optimized for maximal therapeutic benefit with minimal adverse effects.

Toward an AI-integrated translational pipeline

An AI-enabled development pipeline for synergistic anti-Parkinsonian herbal formulations may involve:

- Data mining of ethnopharmacological and molecular databases
- Network-based target prediction and pathway enrichment analysis
- Phytochemical prioritization through DL docking models
- AI-guided formulation optimization
- Preclinical validation using biomarker-driven endpoints
- Adaptive clinical trial modelling.

Such an integrative approach bridges traditional botanical knowledge with modern computational neuroscience, accelerating discovery while enhancing scientific rigor.

AI-INTEGRATED FRAMEWORK FOR SYNERGISTIC POLYHERBAL ANTI-PARKINSONIAN DEVELOPMENT

The convergence of phytopharmacology, systems biology, and AI provides an opportunity to design rational, evidence-based polyherbal therapies for PD. An AI-integrated translational framework ensures that herbal combinations are not empirically selected but computationally prioritized, mechanistically validated, and analytically standardized.

Data collection and curation

The first step involves systematic aggregation of multi-layered datasets, including:

- Phytochemical databases (compound structures, physicochemical properties)
- PD-associated gene and protein databases
- Transcriptomic and proteomic datasets from PD patients
- Published ethnopharmacological literature
- Clinical trial repositories.

NLP tools can extract herb-disease associations from scientific literature. Data harmonization and curation are essential to reduce bias and ensure reliability before computational modelling.[75]

Computational target mapping and network construction

Using machine learning and graph-based algorithms, phytochemicals are mapped to predicted molecular targets. Herb-compound-target-pathway interaction networks are constructed, and pathway enrichment analysis identifies key PD-related signaling cascades influenced by each botanical.

Network centrality metrics help prioritize phytochemicals that influence major pathogenic hubs such as oxidative stress regulation, mitochondrial function, and inflammatory signaling. This computational filtering reduces experimental workload and guides rational formulation design.[76]

AI-guided synergy modeling

Combination modeling algorithms (e.g., synergy prediction models, DL interaction matrices) can simulate potential interactions between phytochemicals. These models predict whether combinations will produce additive, synergistic, or antagonistic effects.

Dose optimization can be guided by reinforcement learning frameworks, ensuring maximal therapeutic effect with minimal toxicity. Such predictive synergy modeling strengthens the scientific foundation of polyherbal design.

AI-assisted formulation and stability optimization

Machine learning models can optimize extraction conditions, excipient selection, nanoparticle composition, and delivery system design. Predictive modeling of solubility, permeability, and BBB penetration supports rational dosage form development.

AI-driven stability forecasting can estimate degradation kinetics under various environmental conditions, reducing the time required for accelerated stability studies.[77]

Experimental validation workflow

The computational predictions must be validated through a structured experimental sequence:

- *In vitro* mechanistic assays
- Toxin-induced animal models

- Biomarker profiling
- Pharmacokinetic assessment
- Safety and toxicity studies.

AI can assist in interpreting multidimensional datasets generated at each stage, identifying patterns that may not be evident through traditional statistical methods.

Regulatory documentation and digital integration

AI-enabled data management systems can automate compilation of regulatory dossiers, integrate analytical quality control records, and generate traceable documentation aligned with GMP. Such automation improves transparency, reproducibility, and compliance readiness.[78]

CHALLENGES, ETHICAL CONSIDERATIONS, AND TRANSLATIONAL BARRIERS

While the integration of herbal medicine and AI offers transformative potential, several challenges must be addressed.[79]

Standardization complexity

Botanical variability remains a major hurdle. Environmental factors influence phytochemical content, complicating reproducibility. Multi-component extracts further increase analytical complexity.

Limited high-quality clinical evidence

Many herbal candidates demonstrate strong preclinical data but lack large-scale randomized clinical trials. Without rigorous clinical validation, therapeutic claims remain preliminary.

Herb-drug interactions

Given that PD patients commonly receive dopaminergic therapy, potential pharmacokinetic or pharmacodynamic interactions must be carefully evaluated. Botanical L-DOPA sources, for example, may unpredictably alter plasma dopamine levels.

AI bias and data quality limitations

AI systems are only as reliable as the datasets on which they are trained. Incomplete, biased, or poorly curated datasets may produce misleading predictions. Transparent algorithm validation and reproducibility are essential.

Ethical and intellectual property considerations

Integration of traditional knowledge with AI-driven drug discovery raises questions regarding intellectual property rights, benefit sharing, and ethical commercialization of indigenous botanical resources.

FUTURE PERSPECTIVES

The future of herbal anti-Parkinsonian therapy lies in precision, personalization, and integration. Advances in omics technologies may enable patient stratification based on molecular signatures. Tailored polyherbal formulations could target dominant pathogenic pathways in individual patients. AI-driven decision support systems may analyze patient data, including genetics, symptom profiles, and medication history to recommend optimized herbal adjuncts alongside conventional therapy. Rather than replacing standard pharmacotherapy, evidence-based herbal formulations may serve as adjunctive agents to reduce oxidative stress, mitigate neuroinflammation, and potentially slow disease progression. Combination strategies must be scientifically validated to ensure safety and efficacy. Emerging nanocarrier systems may enhance brain targeting of phytoconstituents, overcoming bioavailability barriers. AI-optimized nanoformulations could represent the next generation of phytopharmaceuticals.

CONCLUSION

PD remains a progressive and multifactorial neurodegenerative disorder with a significant global burden and limited disease-modifying therapies. While current pharmacological interventions provide symptomatic relief, long-term complications and therapeutic gaps necessitate innovative strategies.

Medicinal plants offer multi-target mechanisms that align with the complex pathology of PD. Synergistic polyherbal formulations, when scientifically standardized and rigorously validated, hold promise as complementary therapeutic options. However, successful translation requires advanced formulation design, stringent quality control, comprehensive preclinical and clinical evaluation, and regulatory compliance.

AI emerges as a powerful integrative tool capable of accelerating phytochemical discovery, predicting synergistic interactions, optimizing formulations, enhancing quality control, and enabling precision phytotherapy. The convergence of traditional botanical knowledge, modern analytical chemistry, systems pharmacology, and AI-driven modeling establishes a robust foundation for next-generation anti-Parkinsonian phytopharmaceutical development.

Future research must prioritize mechanistic validation, standardized extraction protocols, well-designed clinical

trials, and ethical implementation frameworks. Through interdisciplinary collaboration, synergistic herbal formulations may evolve from empirical remedies into scientifically substantiated adjuncts for PD management.

REFERENCES

1. Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, *et al*. Alpha-Synuclein aggregation in Parkinson's disease. Front Med (Lausanne) 2021;8:736978.
2. Ozansoy M, Başak AN. The central theme of Parkinson's disease: α-synuclein. Mol Neurobiol 2013;47:460-5.
3. Picca A, Calvani R, Coelho-Junior HJ, Landi F, Bernabei R, Marzetti E. Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration. Antioxidants (Basel) 2020;9:647.
4. Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson's disease. Intern Med 2023;62:33-42.
5. Vaou N, Stavropoulou E, Voidarou CC, Tsakris Z, Rozos G, Tsigalou C, *et al*. Interactions between medical plant-derived bioactive compounds: Focus on antimicrobial combination effects. Antibiotics (Basel) 2022;11:1014.
6. De Lima EP, Laurindo LF, Catharin VC, Direito R, Tanaka M, Jasmin Santos German I, *et al*. Polyphenols, alkaloids, and terpenoids against neurodegeneration: Evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence. Metabolites 2025;15:124.
7. Zahra M, Abrahamse H, George BP. Flavonoids: Antioxidant powerhouses and their role in nanomedicine. Antioxidants (Basel) 2024;13:922.
8. Waiwut P, Takomthong P, Anorach R, Lomaboot N, Daodee S, Chulikhit Y, *et al*. Pharmacological evaluation of a traditional thai polyherbal formula for Alzheimer's disease: Evidence from *in vitro* and *in silico* studies. Int J Mol Sci 2025;26:6287.
9. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: Enhancing product quality and safety through robust quality control practices. Front Pharmacol 2023;14:1265178.
10. Noviana E, Indrayanto G, Rohman A. Advances in fingerprint analysis for standardization and quality control of herbal medicines. Front Pharmacol 2022;13:853023.
11. Gathungu RM, Kautz R, Kristal BS, Bird SS, Vouros P. The integration of LC-MS and NMR for the analysis of low molecular weight trace analytes in complex matrices. Mass Spectrom Rev 2020;39:35-54.
12. Prasad EM, Hung SY. Behavioral tests in neurotoxin-induced animal models of Parkinson's disease. Antioxidants (Basel) 2020;9:1007.
13. Czigle S, Nagy M, Mladěnka P, Tóth J, OEMONOM. Pharmacokinetic and pharmacodynamic herb-drug interactions-part I. Herbal medicines of the central nervous system. PeerJ 2023;11:e16149.
14. El-Saadony MT, Saad AM, Mohammed DM, Alkafaas SS, Abd El-Mageed TA, Fahmy MA, *et al*. Plant bioactive compounds: Extraction, biological activities, immunological, nutritional aspects, food application, and human health benefits-a comprehensive review. Front Nutr 2025;12:1659743.
15. Twala B. AI-driven precision diagnosis and treatment in Parkinson's disease: A comprehensive review and experimental analysis. Front Aging Neurosci 2025;17:1638340.
16. Yang L, Wang H, Zhu Z, Yang Y, Xiong Y, Cui X, *et al*. Network pharmacology-driven sustainability: AI and multi-omics synergy for drug discovery in traditional Chinese medicine. Pharmaceuticals (Basel) 2025;18:1074.
17. Nagy B, Galata DL, Farkas A, Nagy ZK. Application of artificial neural networks in the process analytical technology of pharmaceutical manufacturing-a review. AAPS J 2022;24:74.
18. Cai H, Xing X, Su Y, Yang C. Innovative applications and future perspectives of chromatography-mass spectrometry in drug research. Front Pharmacol 2025;16:1529468.
19. Akgüller Ö, Balcı MA, Cioca G. A multi-modal graph neural network framework for Parkinson's disease therapeutic discovery. Int J Mol Sci 2025;26:4453.
20. Weintraub D, Burn DJ. Parkinson's disease: The quintessential neuropsychiatric disorder. Mov Disord 2011;26:1022-31.
21. Casanova G, Martarelli R, Belletti F, Moreno-Castro C, Lamura G. The impact of long-term care needs on the socioeconomic deprivation of older people and their families: Results from mixed-methods scoping review. Healthcare (Basel) 2023;11:2593.
22. Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X. Projection of the prevalence of Parkinson's disease in the coming decades: Revisited. Mov Disord 2018;33:156-9.
23. Ramesh S, Arachchige AS. Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS Neurosci 2023;10:200-31.
24. Rangel-Barajas C, Coronel I, Florán B. Dopamine receptors and neurodegeneration. Aging Dis 2015;6:349-68.
25. Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, *et al*. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: A prodromal Parkinson's disease model. Brain 2020;143:249-65.
26. Chai C, Lim KL. Genetic insights into sporadic Parkinson's disease pathogenesis. Curr Genomics 2013;14:486-501.
27. Magrinelli F, Picelli A, Tocco P, Federico A, Roncari L, Smania N, *et al*. Pathophysiology of motor dysfunction

in Parkinson's disease as the rationale for drug treatment and rehabilitation. Parkinsons Dis 2016;2016:9832839.
28. Peña-Zelayeta L, Delgado-Minjares KM, Villegas-Rojas MM, León-Arcia K, Santiago-Balmaseda A, Andrade-Guerrero J, *et al*. Redefining Non-Motor Symptoms in Parkinson's disease. J Pers Med 2025;15:172.
29. Krüger R, Klucken J, Weiss D, Tönges L, Kolber P, Unterecker S, *et al*. Classification of advanced stages of Parkinson's disease: Translation into stratified treatments. J Neural Transm (Vienna) 2017;124:1015-27.
30. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: An old drug still going strong. Clin Interv Aging 2010;5:229-38.
31. Kwon DK, Kwatra M, Wang J, Ko HS. Levodopa-induced dyskinesia in Parkinson's disease: Pathogenesis and emerging treatment strategies. Cells 2022;11:3736.
32. Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW, *et al*. Deep brain stimulation: Current challenges and future directions. Nat Rev Neurol 2019;15:148-60.
33. Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. Semin Neurol 2017;37:147-57.
34. Downing J, Taylor R, Mountain R, Barr B, Daras K, Comerford T, *et al*. Socioeconomic and health factors related to polypharmacy and medication management: Analysis of a household health survey in North West Coast England. BMJ Open 2022;12:e054584.
35. Roy A, Khan A, Ahmad I, Alghamdi S, Rajab BS, Babalghith AO, *et al*. Flavonoids a bioactive compound from medicinal plants and its therapeutic applications. Biomed Res Int 2022;2022:5445291.
36. Tüğen A, Buruleanu CL. The role of plant-derived bioactive compounds in mitigating oxidative stress. Foods 2025;15:108.
37. Nesci S, Spagnoletta A, Oppedisano F. Inflammation, mitochondria and natural compounds together in the circle of trust. Int J Mol Sci 2023;24:6106.
38. Mikulska P, Malinowska M, Ignacyk M, Szustowski P, Nowak J, Pesta K, *et al*. Ashwagandha *(Withania somnifera)*-current research on the health-promoting activities: A narrative review. Pharmaceutics 2023;15:1057.
39. Javed H, Nagoor Meeran MF, Azimullah S, Adem A, Sadek B, Ojha SK. Plant extracts and phytochemicals targeting α-synuclein aggregation in Parkinson's disease models. Front Pharmacol 2019;9:1555.
40. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2. Nat Prod Rep 2019;36:869-88.
41. Velikic G, Supic G, Maric DL, Puletic M, Ovcak Kos M, Vojvodic D, *et al*. Neurodegeneration as ecosystem failure: A new paradigm for prevention and treatment. Int J Mol Sci 2025;26:11207. Erratum in: Int J Mol Sci 2025;26:12153.
42. Rijntjes M. Knowing your beans in Parkinson's disease: A critical assessment of current knowledge about different beans and their compounds in the treatment of Parkinson's disease and in animal models. Parkinsons Dis 2019;2019:1349509.
43. Pirintsos S, Panagiotopoulos A, Bariotakis M, Daskalakis V, Lionis C, Sourvinos G, *et al*. From traditional ethnopharmacology to modern natural drug discovery: A methodology discussion and specific examples. Molecules 2022;27:4060.
44. Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of *Mucuna pruriens*. J Tradit Complement Med 2012;2:331-9.
45. Jamnekar PP, Dehankar TJ, Bedre RV, Dharan BG, Agravat B, Agravat H. Ashwagandha as an adaptogenic herb: A comprehensive review of immunological and neurological effects. Cureus 2025;17:e96183.
46. Dipankar SP, Dani MM, Anirudhan R, Tripathi D, Mishra C, Devi SH. Pharmacological insights into ashwagandha (*Withania somnifera*): A review of its immunomodulatory and neuroprotective properties. Cureus 2025;17:e89856.
47. Tian WW, Liu L, Chen P, Yu DM, Li QM, Hua H, Zhao JN. *Curcuma Longa* (turmeric): from traditional applications to modern plant medicine research hotspots. Chin Med 2025;20:76.
48. Noor-E-Tabassum, Das R, Lami MS, Chakraborty AJ, Mitra S, Tallei TE, *et al*. *Ginkgo biloba*: A treasure of functional phytochemicals with multimedicinal applications. Evid Based Complement Alternat Med 2022;2022:8288818.
49. Valotto Neto LJ, Reverete de Araujo M, Moretti Junior RC, Mendes Machado N, Joshi RK, Dos Santos Buglio D, *et al*. Investigating the neuroprotective and cognitive-enhancing effects of *Bacopa monnieri*: A systematic review focused on inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. Antioxidants (Basel) 2024;13:393.
50. Panossian AG, Efferth T, Shikov AN, Pozharitskaya ON, Kuchta K, Mukherjee PK, *et al*. Evolution of the adaptogenic concept from traditional use to medical systems: Pharmacology of stress- and aging-related diseases. Med Res Rev 2021;41:630-703.
51. Cohen PA, Avula B, Katragunta K, Khan I. Levodopa content of *Mucuna pruriens* supplements in the NIH dietary supplement label database. JAMA Neurol 2022;79:1085-6.
52. Hammoud F, Ismail A, Zaher R, El Majzoub R, Abou-Abbas L. *Mucuna pruriens* treatment for Parkinson disease: A systematic review of clinical trials. Parkinsons Dis 2025;2025:1319419.
53. Soumyanath A, Denne T, Hiller A, Ramachandran S, Shinto L. Analysis of levodopa content in commercial *Mucuna pruriens* products using high-performance liquid chromatography with fluorescence detection. J Altern Complement Med 2018;24:182-6.
54. Parvin N, Aslam M, Joo SW, Mandal TK.

Nano-phytomedicine: Harnessing plant-derived phytochemicals in nanocarriers for targeted human health applications. Molecules 2025;30:3177.
55. Popovic L, Rijkers GT. Phytochemicals: Principles and practice. Biology (Basel) 2025;15:18.
56. Bertoncini-Silva C, Vlad A, Ricciarelli R, Giacomo Fassini P, Suen VM, Zingg JM. Enhancing the bioavailability and bioactivity of curcumin for disease prevention and treatment. Antioxidants (Basel) 2024;13:331.
57. Tallarida RJ. Quantitative methods for assessing drug synergism. Genes Cancer 2011;2:1003-8.
58. Hao M, Tan X, Liu K, Xin N. Nanoencapsulation of nutraceuticals: Enhancing stability and bioavailability in functional foods. Front Nutr 2026;12:1746176.
59. Zhao W, Cui H, Liu J, Sun H, Zhang Z, Zhang Z, *et al*. Herbal interventions in Parkinson's disease: A systematic review of preclinical studies. Cell Mol Neurobiol 2025;45:50.
60. Cheruku S, Darna B, Medipalli V, Nekkalapudi AR, Sadasivam RK. Bioanalytical method development and validation for the quantitation of larotrectinib in human plasma: Application to pharmacokinetics in healthy rabbits. J Appl Pharm Sci 2023;13:111-8.
61. Kellogg JJ, Paine MF, McCune JS, Oberlies NH, Cech NB. Selection and characterization of botanical natural products for research studies: A NaPDI center recommended approach. Nat Prod Rep 2019;36:1196-221.
62. Aktaş E, Hanağası HA, Özgentürk NÖ. Levodopa and plant-derived bioactive compounds in Parkinson's disease: Mechanisms, efficacy, and future perspectives. CNS Neurosci Ther 2025;31:e70540.
63. Sharma S. Current status of herbal product: Regulatory overview. J Pharm Bioallied Sci 2015;7:293-6.
64. Lun Z, Wu X, Dong J, Wu B. Deep learning-enhanced spectroscopic technologies for food quality assessment: Convergence and emerging frontiers. Foods 2025;14:2350.
65. Magalingam KB, Somanath SD, Ramdas P, Haleagrahara N, Radhakrishnan AK. 6-hydroxydopamine induces neurodegeneration in terminally differentiated SH-SY5Y neuroblastoma cells via enrichment of the nucleosomal degradation pathway: A global proteomics approach. J Mol Neurosci 2022;72:1026-46.
66. Casanova Y, Negro S, Barcia E. Application of neurotoxin- and pesticide-induced animal models of Parkinson's disease in the evaluation of new drug delivery systems. Acta Pharm 2021;72:35-58.
67. Yetgin A. Revolutionizing multi-omics analysis with artificial intelligence and data processing. Quant Biol 2025;13:e70002.
68. Spanakis M, Tzamali E, Tzedakis G, Koumpouzi C, Pediaditis M, Tsatsakis A, et al. Artificial intelligence models and tools for the assessment of drug-herb interactions. Pharmaceuticals (Basel) 2025;18:282.
69. Sanches PH, De Melo NC, Porcari AM, De Carvalho LM. Integrating molecular perspectives: Strategies for comprehensive multi-omics integrative data analysis and machine learning applications in transcriptomics, proteomics, and metabolomics. Biology (Basel) 2024;13:848.
70. Golder S, Xu D, O'Connor K, Wang Y, Batra M, Hernandez GG. Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health/medical records: A scoping review. Drug Saf 2025;48:321-37.
71. Shahidi F, Samarasinghe A. How to assess antioxidant activity? Advances, limitations, and applications of *in vitro*, *in vivo*, and *ex vivo* approaches. Food Prod Process Nutr 2025;7:50.
72. Mottaghi-Dastjerdi N, Soltany-Rezaee-Rad M. Advancements and applications of artificial intelligence in pharmaceutical sciences: A comprehensive review. Iran J Pharm Res 2024;23:e150510.
73. Li J, Zhang J, Guo R, Dai J, Niu Z, Wang Y, *et al*. Progress of machine learning in the application of small molecule druggability prediction. Eur J Med Chem 2025;285:117269.
74. Aktary N, Jeong Y, Oh S, Shin Y, Sung Y, Rahman M, *et al*. Unveiling the therapeutic potential of natural products in Alzheimer's disease: Insights from *in vitro*, *in vivo*, and clinical studies. Front Pharmacol 2025;16:1601712.
75. Peng J, Zhao M, Havrilla J, Liu C, Weng C, Guthrie W, *et al*. Natural language processing (NLP) tools in extracting biomedical concepts from research articles: A case study on autism spectrum disorder. BMC Med Inform Decis Mak 2020;20 Suppl 11:322.
76. Yoo S, Yang HC, Lee S, Shin J, Min S, Lee E, *et al*. A deep learning-based approach for identifying the medicinal uses of plant-derived natural compounds. Front Pharmacol 2020;11:584875.
77. Han Y, Kim DH, Pack SP. Nanomaterials in drug delivery: Leveraging artificial intelligence and big data for predictive design. Int J Mol Sci 2025;26:11121.
78. Ajmal CS, Yerram S, Abishek V, Nizam VP, Aglave G, Patnam JD, *et al*. Innovative approaches in regulatory affairs: Leveraging artificial intelligence and machine learning for efficient compliance and decision-making. AAPS J 2025;27:22.
79. Goel S, Matsabisa M, Jiao F, Portella C, Asthana V, Ekandzi N, *et al*. Traditional knowledge on health: Balancing innovation, ethics and intellectual property. Bull World Health Organ 2025;103:708-14.

Source of Support: Nil. **Conflicts of Interest:** None declared.